PT3769781T - Formulação anti-ifnar1 estável - Google Patents

Formulação anti-ifnar1 estável

Info

Publication number
PT3769781T
PT3769781T PT201748050T PT20174805T PT3769781T PT 3769781 T PT3769781 T PT 3769781T PT 201748050 T PT201748050 T PT 201748050T PT 20174805 T PT20174805 T PT 20174805T PT 3769781 T PT3769781 T PT 3769781T
Authority
PT
Portugal
Prior art keywords
ifnar1
formulation
stable anti
stable
ifnar1 formulation
Prior art date
Application number
PT201748050T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58052002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3769781(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT3769781T publication Critical patent/PT3769781T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
PT201748050T 2015-08-19 2016-08-18 Formulação anti-ifnar1 estável PT3769781T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562207164P 2015-08-19 2015-08-19

Publications (1)

Publication Number Publication Date
PT3769781T true PT3769781T (pt) 2023-06-19

Family

ID=58052002

Family Applications (2)

Application Number Title Priority Date Filing Date
PT201748050T PT3769781T (pt) 2015-08-19 2016-08-18 Formulação anti-ifnar1 estável
PT168378180T PT3337502T (pt) 2015-08-19 2016-08-18 Formulação anti-ifnar1 estável

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT168378180T PT3337502T (pt) 2015-08-19 2016-08-18 Formulação anti-ifnar1 estável

Country Status (23)

Country Link
US (1) US10125195B2 (enExample)
EP (3) EP4233892A3 (enExample)
JP (4) JP6720293B2 (enExample)
KR (4) KR102669174B1 (enExample)
CN (1) CN107921109A (enExample)
AU (3) AU2016308262C1 (enExample)
CA (1) CA2995222C (enExample)
CY (2) CY1123657T1 (enExample)
DK (2) DK3769781T5 (enExample)
ES (2) ES2947488T3 (enExample)
FI (1) FI3769781T3 (enExample)
HR (2) HRP20230463T1 (enExample)
HU (2) HUE051862T2 (enExample)
IL (1) IL257279B2 (enExample)
LT (2) LT3769781T (enExample)
PL (2) PL3337502T3 (enExample)
PT (2) PT3769781T (enExample)
RS (2) RS64263B1 (enExample)
RU (1) RU2731737C2 (enExample)
SG (1) SG10202106970XA (enExample)
SI (2) SI3769781T1 (enExample)
SM (2) SMT202300176T1 (enExample)
WO (1) WO2017031288A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102669174B1 (ko) 2015-08-19 2024-06-10 아스트라제네카 아베 안정한 항-ｉｆｎａｒ1 제형
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
PL4058060T3 (pl) * 2019-11-11 2025-07-28 Astrazeneca Ab Hamowanie interferonu typu i w toczniu rumieniowatym układowym
KR20230018446A (ko) * 2020-05-29 2023-02-07 아스트라제네카 아베 I형 인터페론 신호전달 억제제를 이용한 심장대사 질환의 치료
WO2021260193A1 (en) 2020-06-25 2021-12-30 Medimmune Limited Prevention of axonal damage using antibody binding to amyloid beta 1-42
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
PT4192882T (pt) 2021-04-23 2025-05-02 Astrazeneca Ab Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i
CN117157099A (zh) * 2021-04-23 2023-12-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
WO2022223770A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of cutaneous lupus erythematous
EP4306541A3 (en) 2021-04-23 2024-03-27 Astrazeneca AB Anti-ifnar1 dosing regime for subcutaneous injection
JP2024516886A (ja) 2021-05-12 2024-04-17 アストラゼネカ・アクチエボラーグ 全身性エリテマトーデス患者における１型インターフェロン受容体阻害剤のステロイド節約
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
CN113527490B (zh) * 2021-07-13 2022-03-01 江苏荃信生物医药股份有限公司 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
WO2023006700A1 (en) 2021-07-27 2023-02-02 Astrazeneca Ab Treatment of lupus
CN118076379A (zh) 2021-10-04 2024-05-24 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2023073469A1 (en) * 2021-10-29 2023-05-04 Intas Pharmaceuticals Ltd. STABLE LYOPHILIZED FORMULATION OF AN ANTI-α4ß7 ANTIBODY
WO2023155902A1 (en) * 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
WO2024009205A1 (en) * 2022-07-06 2024-01-11 Intas Pharmaceuticals Ltd. STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY
JP2025533978A (ja) 2022-10-13 2025-10-09 アストラゼネカ・アクチエボラーグ ループスの治療
WO2024241156A1 (en) 2023-05-19 2024-11-28 Astrazeneca Ab Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TW200831133A (en) * 2006-12-11 2008-08-01 Hoffmann La Roche Mab Abeta lyophylized formulation
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
SI2250279T1 (sl) * 2008-02-08 2016-10-28 Medimmune, Llc Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
SG11201400815TA (en) * 2011-10-12 2014-09-26 Ascendis Pharma Ophthalmology Division As Prevention and treatment of ocular conditions
WO2013063510A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
KR20150070384A (ko) * 2012-10-25 2015-06-24 메디뮨 엘엘씨 안정한 저점도 항체 제제
CA2910065C (en) * 2013-05-15 2023-09-19 Medimmune Limited Purification of recombinantly produced polypeptides
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US20160250329A1 (en) 2013-10-29 2016-09-01 Albumedix A/S Antibody composition
AU2015310879A1 (en) 2014-09-03 2017-03-02 Medimmune Limited Stable anti-IL-4R-alpha antibody formulation
WO2016109822A1 (en) 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
KR102669174B1 (ko) 2015-08-19 2024-06-10 아스트라제네카 아베 안정한 항-ｉｆｎａｒ1 제형

Also Published As

Publication number Publication date
EP3337502A1 (en) 2018-06-27
KR20180041173A (ko) 2018-04-23
AU2016308262C1 (en) 2022-04-21
AU2020203306B2 (en) 2021-09-09
KR20220127378A (ko) 2022-09-19
LT3337502T (lt) 2020-09-25
HRP20230463T1 (hr) 2023-07-21
JP7035119B2 (ja) 2022-03-14
AU2020203306A1 (en) 2020-06-11
EP3337502A4 (en) 2019-01-23
US20170051066A1 (en) 2017-02-23
AU2016308262A1 (en) 2018-03-08
AU2020203306C1 (en) 2022-03-31
EP4233892A3 (en) 2023-10-25
EP3769781B1 (en) 2023-04-19
WO2017031288A1 (en) 2017-02-23
AU2021257915A1 (en) 2021-11-18
CY1126062T1 (el) 2023-11-15
ES2947488T3 (es) 2023-08-10
JP2022066345A (ja) 2022-04-28
DK3769781T5 (da) 2024-08-19
JP2020158527A (ja) 2020-10-01
EP3337502B1 (en) 2020-06-24
HK1256195A1 (en) 2019-09-13
CY1123657T1 (el) 2022-03-24
DK3337502T3 (da) 2020-09-14
CA2995222C (en) 2021-07-13
HUE061985T2 (hu) 2023-09-28
HRP20201297T1 (hr) 2020-11-27
JP6720293B2 (ja) 2020-07-08
ES2818229T3 (es) 2021-04-09
RU2018107725A (ru) 2019-09-19
BR112018002196A8 (pt) 2021-05-04
RU2731737C2 (ru) 2020-09-08
LT3769781T (lt) 2023-06-12
PT3337502T (pt) 2020-09-23
JP2018523676A (ja) 2018-08-23
SI3337502T1 (sl) 2020-10-30
IL257279B2 (en) 2023-04-01
PL3337502T3 (pl) 2021-01-11
RU2018107725A3 (enExample) 2019-10-02
SMT202300176T1 (it) 2023-07-20
RS60773B1 (sr) 2020-10-30
IL257279B (en) 2022-12-01
KR20240090616A (ko) 2024-06-21
KR20200119916A (ko) 2020-10-20
HUE051862T2 (hu) 2021-03-29
SMT202000483T1 (it) 2020-11-10
SI3769781T1 (sl) 2023-06-30
KR102669174B1 (ko) 2024-06-10
AU2016308262B2 (en) 2020-04-30
EP3769781A1 (en) 2021-01-27
RS64263B1 (sr) 2023-07-31
SG10202106970XA (en) 2021-07-29
JP2024161043A (ja) 2024-11-15
IL257279A (en) 2018-03-29
EP4233892A2 (en) 2023-08-30
BR112018002196A2 (pt) 2019-04-30
KR102168005B1 (ko) 2020-10-21
US10125195B2 (en) 2018-11-13
FI3769781T3 (fi) 2023-06-07
DK3769781T3 (da) 2023-06-19
CA2995222A1 (en) 2017-02-23
PL3769781T3 (pl) 2023-07-17
CN107921109A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
IL257279A (en) Anti-Epner 1 formulation is stable
GB2551985B (en) Novel formulation
GB201513010D0 (en) Novel formulation
GB201407934D0 (en) Formulation
HUE070183T2 (hu) Szilárd formuláció
GB201514758D0 (en) Formulation
PT3173071T (pt) Formulação de maropitant
GB201407384D0 (en) Formulation
IL248835B (en) A preparation of ciritinib
GB201608356D0 (en) Formulation
GB201511301D0 (en) Formulation
IL251362A0 (en) formulation
GB201521771D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201707615D0 (en) Formulation
PL3559185T3 (pl) Preparat nabłyszczający
GB201514014D0 (en) Formulation
GB201504662D0 (en) Formulation
GB201609925D0 (en) Formulation
GB201508527D0 (en) Novel formulation
GB201602048D0 (en) Formulation
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations
GB201416536D0 (en) Formulation